eIF3 α Antibodies

Santa Cruz Biotechnology delivers a wide array of eIF3 α Antibodies for investigating the role of this essential protein in cellular processes. eIF3 α Antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). eIF3 α is a critical component of the eukaryotic translation initiation factor 3 complex, playing a vital role in the initiation of protein synthesis. It is involved in the recruitment of mRNA and the ribosomal subunit, making it essential for proper gene expression and cellular function. Dysregulation of eIF3 α has been implicated in various diseases, including cancer, highlighting its importance as a target for therapeutic intervention. Research has shown that eIF3 α expression levels can serve as potential biomarkers for disease progression and treatment response. Understanding eIF3 α's regulatory mechanisms can provide valuable insights into cellular homeostasis and disease development. Recent studies have revealed new functions of eIF3 α beyond its classical role in translation initiation. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of eIF3 α's role in health and disease.